Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: Thomas who wrote (199)	3/22/2004 1:13:48 PM
From: Thomas	Respond to of 671

atugen presenting at Sachs-Bloomberg in Boston. Sirna still owns a piece of atugen, though not sure how much anymore. Cheers, Thomas Sachs-Bloomberg Global Biotech Forum for Investing & Partnering 2004 Participant Profiles BIOWIRE2K Global Biotech Investor Forum 2004 BOSTON--(BUSINESS WIRE)--March 17, 2004--The Sachs-Bloomberg Annual Global Biotech Forum for Investing & Partnering takes place April 1-2, 2004, at the Fairmont Copley Plaza in Boston. For in-depth information about the event, visit sachsforum.com. Below are profiles from Global Biotech Forum presenters. Breaking news releases are available at tradeshownews.com, Business Wire's trade show and conference news resource. Business Wire is the official news wire service for the Sachs-Bloomberg Global Biotech Forum for Investing & Partnering. <SNIP> Company: atugen AG Media Contact: Thomas Christely Phone:+49 30 9489 2800 E-mail: christely@atugen.com Company URL: www.atugen.com Product description: --siRNA therapeutic candidates in Diabetes and Oncology --Pipeline of proprietary novel and functionally validated cancer targets --Largest set of KnockDown technologies (low toxic GeneBlocs antisense molecules, stabilized synthetic siRNA) --Superior delivery reagents transfecting almost all cell types (transfection rate greater than 95%) Company description: atugen AG is a technology leader in functional gene silencing. The company is based in Berlin, Germany, and currently has about 40 employees. atugen's in-house drug development programs mainly focus on the generation of novel siRNA therapeutics. Here, the company exploits its expertise in oligonucleotide delivery and its recently discovered, chemically-stabilized, proprietary siRNA structures. With its contract research business , the company offers its expertise in target validation and drug discovery to biopharmaceutical customers and partners through research alliances and on a fee-for-service basis.